Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2014 1
2015 1
2017 1
2018 1
2020 3
2021 3
2022 6
2023 11
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

24 results

Results by year

Filters applied: . Clear all
Page 1
Extensive preclinical evaluation of lutetium-177-labeled PSMA-specific tracers for prostate cancer radionuclide therapy.
Ruigrok EAM, van Vliet N, Dalm SU, de Blois E, van Gent DC, Haeck J, de Ridder C, Stuurman D, Konijnenberg MW, van Weerden WM, de Jong M, Nonnekens J. Ruigrok EAM, et al. Among authors: stuurman d. Eur J Nucl Med Mol Imaging. 2021 May;48(5):1339-1350. doi: 10.1007/s00259-020-05057-6. Epub 2020 Oct 23. Eur J Nucl Med Mol Imaging. 2021. PMID: 33094433 Free PMC article.
First preclinical evaluation of [225Ac]Ac-DOTA-JR11 and comparison with [177Lu]Lu-DOTA-JR11, alpha versus beta radionuclide therapy of NETs.
Handula M, Beekman S, Konijnenberg M, Stuurman D, de Ridder C, Bruchertseifer F, Morgenstern A, Denkova A, de Blois E, Seimbille Y. Handula M, et al. Among authors: stuurman d. EJNMMI Radiopharm Chem. 2023 Jun 30;8(1):13. doi: 10.1186/s41181-023-00197-0. EJNMMI Radiopharm Chem. 2023. PMID: 37389800 Free PMC article.
Darolutamide added to docetaxel augments antitumor effect in models of prostate cancer through cell cycle arrest at the G1-S transition.
Buck SAJ, Van Hemelryk A, de Ridder C, Stuurman D, Erkens-Schulze S, Van 't Geloof S, Teubel WJ, Koolen SLW, Martens-Uzunova ES, van Royen ME, de Wit R, Mathijssen RHJ, van Weerden WM. Buck SAJ, et al. Among authors: stuurman d. Mol Cancer Ther. 2023 Nov 30. doi: 10.1158/1535-7163.MCT-23-0420. Online ahead of print. Mol Cancer Ther. 2023. PMID: 38030379
Darolutamide does not interfere with OATP-mediated uptake of docetaxel.
Buck SAJ, Talebi Z, Drabison T, Jin Y, Gibson AA, Hu P, de Bruijn P, de Ridder CMA, Stuurman D, Hu S, van Weerden WM, Koolen SLW, de Wit R, Sparreboom A, Mathijssen RHJ, Eisenmann ED. Buck SAJ, et al. Among authors: stuurman d. Int J Cancer. 2024 Mar 16. doi: 10.1002/ijc.34922. Online ahead of print. Int J Cancer. 2024. PMID: 38491867
Androgen receptor signalling impairs docetaxel efficacy in castration-resistant prostate cancer.
Mout L, Moll JM, Chen M, de Morrée ES, de Ridder CMA, Gibson A, Stuurman D, Aghai A, Erkens-Schulze S, Mathijssen RHJ, Sparreboom A, de Wit R, Lolkema MP, van Weerden WM. Mout L, et al. Among authors: stuurman d. Br J Cancer. 2020 Dec;123(12):1715-1719. doi: 10.1038/s41416-020-01105-y. Epub 2020 Sep 29. Br J Cancer. 2020. PMID: 32989230 Free PMC article.
Patient-Derived Xenografts and Organoids Recapitulate Castration-Resistant Prostate Cancer with Sustained Androgen Receptor Signaling.
Van Hemelryk A, Tomljanovic I, de Ridder CMA, Stuurman DC, Teubel WJ, Erkens-Schulze S, Verhoef EI, Remmers S, Mahes AJ, van Leenders GJLH, van Royen ME, van de Werken HJG, Grudniewska M, Jenster GW, van Weerden WM. Van Hemelryk A, et al. Among authors: stuurman dc. Cells. 2022 Nov 16;11(22):3632. doi: 10.3390/cells11223632. Cells. 2022. PMID: 36429059 Free PMC article.
24 results